Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 296

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 296
---
 other than the functional currency of the borrower or lender). That foreign exchange exposure is hedged using derivative instruments (foreign exchange swaps, forward contracts or currency swaps) that alter the currency split of Sanofi’s net debt once those instruments are taken into account. The table below shows financial currency hedging instruments in place as of December 31, 2024 , with the notional amounts translated into euros at the relevant closing exchange rate (see also Note D.20. to the consolidated financial statements for the accounting classification of these instruments as of December 31, 2024 ). Financial foreign exchange derivatives as of December 31, 2024

| (€ million)                    | Notional amount |    | Fair value | Expiry |
| Forward currency sales         |          10,377 |    |       -195 |        |
| of which US dollar             |           8,923 | -a |       -176 |   2025 |
| of which Japanese yen          |             371 |    |          4 |   2025 |
| of which Chinese yuan renminbi |             235 |    |         -1 |   2025 |
| Forward currency purchases     |           6,884 |    |        112 |        |
| of which US dollar             |           4,397 | -b |        123 |   2025 |
| of which Singapore dollar      |             819 |    |          2 |   2025 |
| of which Hungarian forint      |             641 |    |         -9 |   2025 |
| Total                          |          17,261 |    |        -83 |        |

(a) Includes forward sales with a notional amount of $3,615 million expiring in 2025 , designated as a hedge of Sanofi’s net investment in Bioverativ. As of December 31, 2024 , the fair value of these forward contracts represented a liability of €88 million ; the opposite entry was recognized in “Other comprehensive income," with the impact on financial income and expense being immaterial. (b) Includes forward purchases with a notional amount of $ 1,000 million expiring in 2025 , designated as a fair value hedge of the exposure of $ 1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2024 , the fair value of the contracts represented an asset of € 75 million